Central memory-enriched Vγ9Vδ2 γδ T cells via TGF-β expansion demonstrate enhanced <i>in vivo</i> efficacy against metastatic osteosarcoma.

ABSTRACT: The application of cellular immunotherapies (CI) for osteosarcoma (OS) has mainly focused on autologous products of αβ T cells and, to date, has shown little clinical benefit. Based on the multi-killing properties of γδ T cells, specifically Vγ9Vδ2 T cells, and their ability to be employed as an allogeneic, off-the-shelf cellular therapy, there is significant interest in this CI. Although there are efficient, clinical-scale expansion protocols, a concern is the short in vivo half-life of these cells due to the terminal differentiated phenotypes of expanded cells. Therefore, modifying the manufacturing process to generate a more memory-like phenotype could overcome hurdles associated with this CI. Transforming growth factor-beta (TGF-β) is a cytokine with multiple functions, and can

SUBMITTER: Silva JA 

PROVIDER: S-EPMC12440941 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature